OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 22
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 22
Showing 22 citing articles:
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Yonglin Hua, Zhixian Sun, Yuxin Xiao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008953-e008953
Open Access | Times Cited: 11
Yonglin Hua, Zhixian Sun, Yuxin Xiao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008953-e008953
Open Access | Times Cited: 11
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
Yufeng Zhang, Haiyan Zhang, Haoqian Xu, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Yufeng Zhang, Haiyan Zhang, Haoqian Xu, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma—A Retrospective Study
Yue Chen, Luyao Jia, Yu Li, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 12, pp. 7860-7869
Closed Access | Times Cited: 5
Yue Chen, Luyao Jia, Yu Li, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 12, pp. 7860-7869
Closed Access | Times Cited: 5
Next‐Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma
Han Wu, Shao-Dong Lv, Renjie Zhang, et al.
Advanced Materials (2025)
Closed Access
Han Wu, Shao-Dong Lv, Renjie Zhang, et al.
Advanced Materials (2025)
Closed Access
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
Zhenkun Huang, Tiejun Chen, Wenbin Li, et al.
International Immunopharmacology (2024) Vol. 139, pp. 112711-112711
Closed Access | Times Cited: 4
Zhenkun Huang, Tiejun Chen, Wenbin Li, et al.
International Immunopharmacology (2024) Vol. 139, pp. 112711-112711
Closed Access | Times Cited: 4
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023
Qifeng Chen, Xiongying Jiang, Minshan Chen, et al.
Annals of Surgery Open (2025) Vol. 6, Iss. 1, pp. e562-e562
Open Access
Qifeng Chen, Xiongying Jiang, Minshan Chen, et al.
Annals of Surgery Open (2025) Vol. 6, Iss. 1, pp. e562-e562
Open Access
Identification of candidates with hepatocellular carcinoma to receive TACE combined with MWA by assessing tumor burden and radiologic features
Chao An, Lujun Shen, Qifeng Chen, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Chao An, Lujun Shen, Qifeng Chen, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma
Xu Zhang, Xu Zhang, Qiankun Luo, et al.
World Journal of Clinical Oncology (2025) Vol. 16, Iss. 4
Closed Access
Xu Zhang, Xu Zhang, Qiankun Luo, et al.
World Journal of Clinical Oncology (2025) Vol. 16, Iss. 4
Closed Access
Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study
Chengyu Liu, Zikang Li, Zhilei Zhang, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Chengyu Liu, Zikang Li, Zhilei Zhang, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study
Hanyu Jiang, Mengxuan Zuo, Wang Li, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 5672-5684
Open Access | Times Cited: 2
Hanyu Jiang, Mengxuan Zuo, Wang Li, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 5672-5684
Open Access | Times Cited: 2
Recent advances in surgical management strategies for hepatocellular carcinoma
Zhen–Bin Ding, Ying‐Hong Shi, Jiafeng Chen, et al.
hLife (2024) Vol. 2, Iss. 9, pp. 439-453
Open Access | Times Cited: 2
Zhen–Bin Ding, Ying‐Hong Shi, Jiafeng Chen, et al.
hLife (2024) Vol. 2, Iss. 9, pp. 439-453
Open Access | Times Cited: 2
The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
Zongren Ding, Guoxu Fang, Yanyan Tang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Zongren Ding, Guoxu Fang, Yanyan Tang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Hongwei Xu, Haili Zhang, Bo Li, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Hongwei Xu, Haili Zhang, Bo Li, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy
Heng Dong, Zhengguo Zhang, Mengjie Ni, et al.
Current Treatment Options in Oncology (2024)
Open Access | Times Cited: 1
Heng Dong, Zhengguo Zhang, Mengjie Ni, et al.
Current Treatment Options in Oncology (2024)
Open Access | Times Cited: 1
Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
Zhonghua Zhao, Xiongying Jiang, Shiping Wen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Zhonghua Zhao, Xiongying Jiang, Shiping Wen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis
Yue Chen, Luyao Jia, Yu Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Yue Chen, Luyao Jia, Yu Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Improving treatment plan and mental health in children with abdominal infection for broad-spectrum bacterial infections
Gui-Bo Wang, Xuefeng Zhang, Bing Liang, et al.
World Journal of Psychiatry (2024) Vol. 14, Iss. 9, pp. 1319-1325
Open Access
Gui-Bo Wang, Xuefeng Zhang, Bing Liang, et al.
World Journal of Psychiatry (2024) Vol. 14, Iss. 9, pp. 1319-1325
Open Access
Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies
xingrong zheng, Xin Song, BoXiang Zhang, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
xingrong zheng, Xin Song, BoXiang Zhang, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
A commentary on “Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study”
Jia Luo, Qian Yang, Wen Ma, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 6045-6046
Open Access
Jia Luo, Qian Yang, Wen Ma, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 6045-6046
Open Access
Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
Feng Han, Xiaohan Wang, Chenzhou Xu
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 7, pp. 3308-3320
Open Access
Feng Han, Xiaohan Wang, Chenzhou Xu
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 7, pp. 3308-3320
Open Access
Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era
Ugo Testa
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 9, pp. 803-827
Open Access
Ugo Testa
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 9, pp. 803-827
Open Access
From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies
Mo-Wei Kong, Yang Yu, Ying Wan, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 11, pp. 4518-4521
Closed Access
Mo-Wei Kong, Yang Yu, Ying Wan, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 11, pp. 4518-4521
Closed Access
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
Hui Yang, Guang-Ping Qiu, Jie Liu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 11, pp. 4392-4401
Closed Access
Hui Yang, Guang-Ping Qiu, Jie Liu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 11, pp. 4392-4401
Closed Access
